



Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1 (currently amended): A method for targeting Hepatic Stellate Cells (HSC) involved in sclerotic and/or fibrotic diseases, and in which cells the PDGF-receptor is upregulated during disease, in a tissue sample of a subject, said method comprising the steps of providing a tissue sample of a subject and administering a carrier molecule to said tissue sample in an effective amount, using a carrier molecule, said carrier molecule being linked to at least one further molecule, said further molecule comprising a cyclic peptide comprising the amino acid sequence SRNLIDC.

Claim 2 (currently amended): A method for targeting Hepatic Stellate Cells (HSC) involved in sclerotic and/or fibrotic diseases, and in which cells the PDGF-receptor is upregulated during disease, in a subject, said method comprising the steps of administering a pharmaceutically acceptable amount and form of a carrier molecule to said subject using, in a pharmaceutically acceptable amount and form of a carrier molecule, said carrier molecule being linked to at least one further molecule, said further molecule comprising a cyclic peptide comprising the amino acid sequence SRNLIDC.

Claim 3 (canceled)

Claim 4 (canceled)

Claim 5 (previously presented): A method according to claim 1 or 2, wherein the carrier molecule comprises additional drugs or chemicals linked thereto.

Claim 6 (previously presented): A method according to claim 1 or 2,

wherein the carrier molecule comprises a diagnostic marker attached thereto.

Claim 7 (previously amended): A method according to claim 1 or 2, wherein the sclerotic or fibrotic disease is liver fibrosis.

Claim 8 (canceled)

Claim 9 (canceled)

Claim 10 (canceled)

Claim 11 (canceled)

Claim 12 (canceled)

Claim 13 (canceled).

Claim 14 (previously amended): A compound comprising a carrier molecule linked to at least one further molecule, said further molecule comprising a cyclic peptide wherein the cyclic portion of said cyclic peptide comprises the amino acid sequence SRNLIDC.

Claim 15 (canceled)

Claim 16 (canceled)

Claim 17 (canceled)

Claim 18 (previously amended): A compound according to claim 14, wherein in the further molecule, the cyclic portion of the cyclic peptide comprises multiple receptor binding sequences.

Claim 19 (previously amended): A compound according to claim 14, wherein in the further molecule, the cyclic portion of the cyclic peptide comprises multiple receptor binding sequences directed at at least two different types of receptors.

Claim 20 (previously presented): A compound according to claim 14, wherein the further molecule comprises multiple cyclic peptides directed at the same or different types of receptors.

Claim 21 (previously presented): A compound according to claim 14, wherein the carrier molecule is selected from the group of carrier molecules consisting of proteins, oligo or polypeptides, immunoglobulins or parts thereof, oligonucleotides, disaccharides, polysaccharides, biodegradable synthetic polymers, liposomes, lipid particles, biocompatible polymers in the form of microspheres or nanoparticles, endogenous plasma proteins, lactoferrin, alkaline phosphatase, superoxide dismutase, alpha2 macroglobulin and fibronectin.

Claim 22 (previously presented): A compound according to claim 14, wherein the carrier molecule comprises additional drugs or chemicals linked thereto.

Claim 23 (previously presented): A compound according to claim 14, wherein the carrier molecule comprises a diagnostic marker attached thereto.

Claim 24 (previously amended): A pharmaceutical composition comprising a compound according to any one of claims 14 or 18-23 as targeting ingredient and one or more pharmaceutically acceptable carriers.

Claim 25 (currently amended): A method ~~of~~ for the in vitro diagnosis of liver fibrosis or kidney fibrosis comprising providing a tissue sample of a subject and administering using a compound according to any one of claims 14 or 18-23 to said tissue sample. ~~for in vitro diagnosis of liver fibrosis or kidney fibrosis.~~

Appln. No. 09/806,837
Amdt. dated July 1, 2004
Reply to Office Action of April 14, 2004

Claim 26 (currently amended): A method ~~of~~ for preparation of a medicament for in vivo diagnosis and/or therapy of liver fibrosis or kidney fibrosis comprising adding a suitable amount of ~~using~~ a compound according to any one of claims 14 or 18-23 to one or more pharmaceutically acceptable carriers. ~~for the preparation of a medicament for in vivo diagnosis, prophylaxis and/or therapy of liver fibrosis or kidney fibrosis.~~

Claim 27 (canceled).

Claim 28 (currently amended): ~~Method~~ A composition according to claim 21, wherein said endogenous plasma protein is albumin.

Claim 29 (previously amended): Method according to claim 25, wherein said liver fibrosis is cirrhosis, or wherein said kidney fibrosis is glomerulosclerosis or interstitial fibrosis.

Claim 30 (previously amended): Method according to claim 26, wherein said liver fibrosis is cirrhosis, or wherein said kidney fibrosis is glomerulosclerosis or interstitial fibrosis.

Claim 31 (currently amended): A method for targeting cells involved in sclerotic and/or fibrotic diseases selected from liver fibrosis and kidney fibrosis, and in which cells the PDGF-receptor is upregulated during said disease, in a tissue sample of a subject, said method comprising providing said tissue sample of a subject and administering to said tissue sample an effective amount of ~~using~~ a carrier molecule, said carrier molecule linked to at least one further molecule, said further molecule comprising a cyclic peptide comprising the amino acid sequence SRNLIDC, wherein said liver fibrosis is liver cirrhosis and said kidney fibrosis is glomerulosclerosis or interstitial fibrosis.

Claim 32 (currently amended): A method for targeting cells involved in sclerotic and/or fibrotic diseases selected from liver fibrosis and kidney fibrosis, and in

Appln. No. 09/806,837
Amdt. dated July 1, 2004
Reply to Office Action of April 14, 2004

which cells the PDGF-receptor is upregulated during said disease, in a subject, said method comprising administering a carrier molecule in a pharmaceutically acceptable amount and form to said subject, using, in a pharmaceutically acceptable amount and form, a carrier molecule, said carrier molecule linked to at least one further molecule, said further molecule comprising a cyclic peptide comprising the amino acid sequence SRNLIDC and wherein said liver fibrosis is liver cirrhosis and wherein said kidney fibrosis is glomerulosclerosis or interstitial fibrosis.

Claim 33 (previously submitted): A method according to claim 31 or 32, wherein the carrier molecule comprises additional drugs or chemicals linked thereto.

Claim 34 (previously submitted): A method according to claim 31 or 32, wherein the carrier molecule comprises a diagnostic marker attached thereto.